Author, as appears in the article.: Villarroel, PG; Padro, JG; Marquina, G; Janez, NM; Gonzalez, EE; Anton, A; Sanchez, MB; Caceres, AR; Lopez-Lopez, R; Cornejo, RE; Garcia, PB; Fabregat, RM; Fernandez, BC; Bermudo, CL; Camps, C
Department: Medicina i Cirurgia
URV's Author/s: Gumà Padró, José
Keywords: Transmucosal fentanyl Rapid-onset opioids Quality of life Medical oncology Management Breakthrough cancer pain transmucosal fentanyl scale rapid-onset opioids quality of life medical oncology
Abstract: Aim: To evaluate the quality of life (QoL) in patients with breakthrough cancer pain (BTcP) in Spanish medical oncology departments. Patients & methods: In a prospective, observational, multicenter study, we assessed QoL using the EQ-5D-5L instrument at baseline and after 15 and 30 days of individualized BTcP therapy, as well as BTcP characteristics and treatment. Results: Patients (n = 118) were mainly women, over 64 years old and with advanced cancer. QoL improved at 15 (p = 0.013) and 30 days (p = 0.011) versus baseline. Individualized BTcP therapy consisted mostly of rapid-onset opioids (transmucosal fentanyl at doses of 67-800 μg) according to the physician evaluation. BTcP improved, including statistically significant reductions in intensity, duration, number of episodes in the last 24 h and time to onset of BTcP relief. Conclusion: QoL increased after individualized pain therapy in patients with advanced cancer and BTcP in medical oncology departments.
Thematic Areas: Oncology Odontología Medicine (miscellaneous) Medicina ii Medicina i Ciências biológicas ii Ciências biológicas i Cancer research Biotecnología Astronomia / física
licence for use: https://creativecommons.org/licenses/by/3.0/es/
Author's mail: jose.guma@urv.cat
Author identifier: 0000-0001-7541-9832
Record's date: 2024-09-07
Papper version: info:eu-repo/semantics/publishedVersion
Link to the original source: https://www.futuremedicine.com/doi/10.2217/fon-2022-0758
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Papper original source: Future Oncology. 18 (35): 3913-3927
APA: Villarroel, PG; Padro, JG; Marquina, G; Janez, NM; Gonzalez, EE; Anton, A; Sanchez, MB; Caceres, AR; Lopez-Lopez, R; Cornejo, RE; Garcia, PB; Fabregat (2022). Increased quality of life in patients with breakthrough cancer pain after individualized therapy: the CAVIDIOM study. Future Oncology, 18(35), 3913-3927. DOI: 10.2217/fon-2022-0758
Article's DOI: 10.2217/fon-2022-0758
Entity: Universitat Rovira i Virgili
Journal publication year: 2022
Publication Type: Journal Publications
Repositori URV